As Dot-coms Reel, Broadlane Steps Forward

While Ventro Corp. announces the closing of two of its B2B e-commerce businesses, its Broadlane business announces a major group purchasing agreement with Kaiser Permanente.

The announcement last month that once high-flying Ventro Corp. , a leader in B2B e-commerce solutions in healthcare, is shutting down its Chemdex and Promedix businesses had to come as something of a surprise, notwithstanding the rumors that had flown for weeks and the general carnage that has taken place in the B2B space over the past several months. There are reports daily of what some in the Internet industry now call "e-bituaries"—companies that go out of business, having used the last of huge amounts of venture capital raised just a year ago—while those that survive are quickly trying to refashion themselves to remove any hint of B2B e-commerce in their business models. Ventro is no exception: the shedding of Chemdex and Promedix are part of the company's effort to reposition itself as, more narrowly, a provider of software procurement solutions.

Still, the announcement from a company widely viewed as a B2B pioneer just months earlier had the bracing feel of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By 

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By 

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.